Seres Therapeutics (MCRB) Tops Q2 EPS by 277c

Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of $0.47, $2.77 better than the analyst estimate of ($2.30). Revenue for the quarter came in at $736 thousand versus the consensus estimate of $358 thousand.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Apple announced foldable iPhone Duo, starting at $1,999
• Medical Properties Trust (MPT) call put ratio 1 call to 6.8 puts with a focus on December 4 calls and June 2.5 puts as share price down 1.6%
• Apple announces A20 Pro chip based on 2nm technology